Business · 26/01/1999Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Anzemet Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Anzemet, a human drug product, in accordance with patent extension regulations, following a submission to the Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →